Target 3 anchor customers: 1 Indian generic pharma (drug repurposing), 1 hospital research arm (biomarker discovery), 1 biotech startup (Discovery Sprint). Co-develop OmicsCloud with them. Use Hyderabad connections (Apollo, Genome Valley ecosystem). BIRAC grant application for non-dilutive capital. Publish 2–3 high-impact papers using India cohort data to establish scientific credibility.
OmicsCloud goes to general availability. LabOS integrations with Syngene and Aragen live. 20–30 customers across three tiers. First international customer (Singapore or Japan). Series A raise. India Biomarker Atlas first licensing deal with MNC pharma. First co-development agreement signed.
Open Singapore entity as the APAC hub. FAL Pods deployed (Phase 2 lab strategy). Series B raise anchored by APAC strategic investors (Temasek, GIC). Government MoU for India rare disease national program. See companion page → Singapore BioHelix Node for the wet-lab operations hub, MiRXES partnership thesis, and India↔Singapore corridor architecture.